{"product_id":"sepsis-isbn-9780470027981","title":"Sepsis","description":"\u003cb\u003e\u003ci\u003eSepsis: New Insights, New Therapies\u003c\/i\u003e\u003c\/b\u003e brings together contributions from an international group of experts in diverse fields to consider how the various pathways implicated in early and late sepsis interact, with a particular emphasis on novel concepts and potential new therapeutic approaches. Topics covered include adaptive immunity, inflammation, neuroendocrinology, bioenergetics and metabolism. Several chapters in the latter half of the book are particularly concerned with treatment strategies involving modulation of the neuroendocrine response.  \u003cul\u003e \u003cli\u003eAddresses the frequent, but under-recognised condition of sepsis and discusses new ways to prevent and treat it\u003c\/li\u003e \u003cli\u003eDescribes numerous pharmacological approaches to therapy for early and late sepsis\u003c\/li\u003e \u003cli\u003eIncludes detailed discussion of the various physiological systems implicated in sepsis\u003c\/li\u003e \u003cli\u003ePresents an international perspective, featuring contributions from experts from laboratories worldwide involved in the study of sepsis\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cb\u003e\u003ci\u003eSepsis: New Insights, New Therapies\u003c\/i\u003e\u003c\/b\u003e is an invaluable resource for all critical care physicians and researchers. It is also informative reading for immunologists, endocrinologists, neuroendocrinologists, physiologists, and pharmacologists.\u003c\/p\u003e  Symposim on Sepsis: new insights, new therapies, held at the Novartis Foundation, London, 14-16 February 2006.  \u003cp\u003eEditors: Derek J. Cahdwick (Organizer) and Jamie Goode.\u003c\/p\u003e \u003cp\u003eThis Symposim was based on a proposal made by Mitchell Fink and Mervyn Singer.\u003c\/p\u003e \u003cp\u003eChair’s introduction \u003cb\u003e(\u003ci\u003eMitchell P. Fink).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStrategies to modulate cellular energetic metabolism during sepsis \u003cb\u003e(\u003ci\u003eAlessandro Protti\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eMervyn Singer).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eImmunostimulation is a rational therapeutic strategy in sepsis \u003cb\u003e(\u003ci\u003eJérôme Pugin).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eBlockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis \u003cb\u003e(\u003ci\u003eAlfred Ayala, Doreen E. Wesche-Soldato, Mario Perl, Joanne L. Lomas-Neira, Ryan Swan\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eChun-Shiang Chung).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eModulating neutrophil apoptosis \u003cb\u003e(\u003ci\u003eJohn C. Marshall, Zeenat Malam\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eSonghui Jia).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eHMGB1 as a potential therapeutic target\u003cb\u003e(\u003ci\u003eHaichao Wang, Wei Li, Richard Goldstein, Kevin J. Tracey\u003c\/i\u003e\u003c\/b\u003e\u003ci\u003eand \u003cb\u003eAndrew E. Sama).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePoly (ADP-ribose) polymerase activation and circulatory shock \u003cb\u003e(\u003ci\u003eCsaba Szabó).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChoosing the right substrate \u003cb\u003e(\u003ci\u003eXavier Leverve, Cécile Batandier\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eEric Fontaine).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eInhibiting glycogen synthase kinase 3β in sepsis \u003cb\u003e(\u003ci\u003eLaura Dugo, Marika Collin, David A. Allen, Nimesh S.A. Patel, Inge Bauer, Eero M. A. Mervaala, Marjut Louhelainen, Simon J. Foster, Muhammad M. Yaqoob\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eChristoph Thiemermann).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eEthyl pyruvate: a novel treatment for sepsis \u003cb\u003e(\u003ci\u003eMitchell P. Fink).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eGeneral discussion I.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eCytoprotective and anti-inflammatory actions of carbon monoxide in organ injury and sepsis models\u003cb\u003e(\u003ci\u003eStefan W. Ryter and Augustine M. K. Choi).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe hypothalamic pituitary adrenal axis in sepsis (\u003cb\u003e\u003ci\u003eAndrea Polito, Jérôme Aboab\u003c\/i\u003e \u003ci\u003eand\u003c\/i\u003e\u003ci\u003eDjillali Annane).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eModulating the endocrine response in sepsis: insulin and blood glucose control \u003cb\u003e(\u003ci\u003eIlse Vanhorebeek, Lies Langouche\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eGreet Van den Berghe).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eThe neuronal strategy for inflammation\u003cb\u003e(\u003c\/b\u003e\u003cb\u003e\u003ci\u003eLuis Ulloa\u003c\/i\u003e\u003c\/b\u003e\u003ci\u003eand \u003cb\u003ePing Wang).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eBeta-blockade in burns \u003cb\u003e(\u003ci\u003eC. T. Pereira, M. G. Jeschke\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eD. N. Herndon).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSystem interactions \u003cb\u003e(\u003ci\u003eMervyn Singer).\u003c\/i\u003e\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eProtecting the permeability pore and mitochondrial biogenesis \u003cb\u003e(\u003ci\u003eC. A. Piantadosi, M. S. Carraway, D. W. Haden\u003c\/i\u003e\u003c\/b\u003e \u003ci\u003eand \u003cb\u003eH. B. Suliman).\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDiscussion.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eContributor Index.\u003c\/p\u003e \u003cp\u003eSubject index.\u003c\/p\u003e  The \u003cb\u003eNovartis Foundation\u003c\/b\u003e is an international scientific and educational charity which promotes the study and general knowledge of science and in particular encourages international co-operation in scientific research.\u003cbr\u003e Chairman: Mitchell Fink  Sepsis, the complex, systemic, clinical syndrome resulting from the innate host inflammatory response to infection, is an increasingly common condition, particularly in an ageing population with multiple comorbidities. The mortality rate remains high – about 30% in the USA and Europe and much higher in the developing world. Indeed, the annual number of deaths from sepsis rivals those due to myocardial infarction and exceeds the mortality rate of virtually every common cancer, yet the syndrome has received relatively little attention as a modifiable disease process.  \u003cp\u003eMost therapeutic strategies target pro-inflammatory mediators, but these have frequently not improved survival of patients when studied in large, multicentre clinical trials. Greater appreciation of the complex pathophysiology by which sepsis induces multiple organ failure has stimulated research into new therapeutic approaches. Depending on the phase of the septic syndrome, these could even involve stimulation of inflammatory, immune or other systems, so the timing of intervention is important. With advances in supportive care in the intensive care unit, the ability to titrate treatment individually is becoming both a reality and a necessity. This important book brings together contributions from an international group of experts in diverse fields, including adaptive immunity, inflammation, neuroendocrinology, bioenergetics and metabolism, to consider all aspects of sepsis and its treatment.\u003c\/p\u003e \u003cp\u003e“The pattern of critical illness has changed, such that sepsis, multiple organ failure and impaired patient immunity now dominate clinical practice. Sadly, despite many therapeutic advances, the mortality of this complex syndrome remains high, posing a major challenge. This book highlights the complexity of the disorder and signals the directions for future therapeutic endeavour.”\u003c\/p\u003e \u003cp\u003eDr Jack Tinker, Emeritus Dean The Royal Society of Medicine, London\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47990007628005,"sku":"NP9780470027981","price":253.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470027981.jpg?v=1761786196","url":"https:\/\/k12savings.com\/products\/sepsis-isbn-9780470027981","provider":"K12savings","version":"1.0","type":"link"}